Release date: 2016-11-02
Recently, Mike biological announcement that the US will soon be due to gene signed an agreement with Zhuhai Yi Jian defender equity investment fund (limited partnership) and other six investors, Mike biological subject acquired 2.57% stake in the company to 30 million yuan capital increase of way . From the ownership structure - Announcement of view, the United States due to genetic round of financing totaling 167 million yuan.
The US gene gene official website shows that it has built a high-standard experimental platform according to the requirements of medical inspection, has a high-throughput sequencing and information analysis platform, uses proprietary technology developed by itself to reduce the cost of testing, and popularizes genetic testing for the general public. The listed products include “Meinan†susceptibility gene detection, early colorectal cancer screening, personal genome detection, sports nutrition gene detection and many other products. It has established cooperative relationships with many medical examination companies and top three hospitals. The core members of the Main Gene are from well-known institutions such as Peking University, Oxford University, and Chinese Academy of Sciences . They have rich experience in entrepreneurship and entrepreneurship in the direction of gene sequencing and artificial intelligence. Mike Bio believes that with the development of precision medicine, genetic diagnosis has become one of the fastest growing segments of the IVD industry, and it is also a new growth point for the future development of the industry. This time, the company is involved in the field of genetic diagnosis, which not only can effectively promote the development of the company's genetic technology research and development platform, but also lay a foundation for the company to expand the precision medical market in the future.
At the same time, Mike Bio also pointed out that the development of the field of genetic diagnosis is greatly influenced by national and industrial policies, while the development of genetic technology has the characteristics of large investment and long cycle. The operation of the Main Gene is affected by various factors such as policy risk, market risk and management risk. In the process of integration, there is a risk that the business development plan is lower than expected and the business development plan fails to be realized on time.
The announcement also shows that the US gene belongs to Maine Health Technology (Beijing) Co., Ltd., registered on January 5, 2016, and the legal representative is Yu Rong, namely Shanghai Tianyi Asset Management Co., Ltd. (referred to as “Tianyi Asset Managementâ€) And the legal representative of the United States and the United States Health Industry Holdings Co., Ltd. (referred to as "the United States and the United States").
In fact, according to the US Great Health Announcement, it had previously purchased a 20% stake in Maine Gene held by Tianyi Asset Management and completed the registration of industrial and commercial changes on July 4, 2016. After the health of the United States became a healthy shareholding company in the United States, it will help the United States to diversify its health checkup products, increase genetic testing and other testing programs, and provide more accurate preventive testing for the nation.
According to Gene, the financing will be used to build large-scale gene sequencing centers and gene-phenotypic data centers in China, and to explore the relationship between individual genomes, proteomes, microbiomes, metabolomes, and mobile intelligent device data. To provide big data support for the discovery of causes, drug research and development, health interventions, etc., to create a leading consumer genetic testing enterprise.
Source: 36æ°ª
Feed Grade Vitamins,Vitamin K Powder,Natural Vitamin E,Bulk Vitamin B Powder
Ningbo Nutrition Food Technology Co.,ltd. , https://www.collagenworkshop.com